Growing Antibiotic Resistance Pathogens is Expected to Drive the Growth of India Community Acquired Pneumonia Drugs Market

The growing rate of antibiotic-resistant pathogens causing pneumonia presents a unique feature for the Community-Acquired Pneumonia (CAP) drug market in India. There is an urgent need for innovative and effective treatments to combat evolving microbial threats, as antibiotic resistance becomes a global concern. India, with its thriving pharmaceutical industry, has the potential to lead in the development of new antibiotics and alternative therapies. Indian pharmaceutical companies can contribute valuable solutions to the global healthcare landscape by investing in research and development to address antibiotic-resistant strains. In addition, initiatives that prioritize research on antibiotic stewardship and combination therapies can further enhance India standing in addressing the complex issue of antibiotic resistance in pneumonia treatment. 

Access Full Report @ https://www.databridgemarketresearch.com/reports/india-community-acquired-pneumonia-drugs-market

Data Bridge Market Research analyses that the India Community Acquired Pneumonia Drugs Market is expected to reach USD 162.51 million by 2031 from USD 92.72 million in 2023 growing at a CAGR of 7.5% in the forecast period of 2024 to 2031.

Key Findings of the Study

Rising Prevalence of Pneumonia

The rising prevalence and burden of pneumonia in India present a substantial opportunity for the Community-Acquired Pneumonia (CAP) drug market in the country. With pneumonia being a leading cause of morbidity and mortality, particularly among vulnerable populations such as children and the elderly, there is an increasing demand for effective and accessible treatments. This heightened need creates a market opportunity for pharmaceutical companies to innovate, develop, and provide a diverse range of pneumonia drugs tailored to address the evolving strains and challenges associated with the disease, which is driving the market growth. 

Report Scope and Market Segmentation

Segment Analysis

India community acquired pneumonia drugs market is categorized into nine notable segments based on product, route of administration, dosage, product type, mode of purchase, type, population type, end user, and distribution channel.

• On the basis of product, the market is segmented into macrolides, b-lactam antibiotics, quinolones, tetracycline, carbapenem, glycopeptide antibiotics, pleuromutilin, and others

In 2024, the macrolides segment is expected to dominate the India community acquired pneumonia drugs market

In 2024, the macrolides segment is expected to dominate the market with a market share of 25.15% due to its broad spectrum activity.

• On the basis of route of administration, the market is segmented into oral and intravenous

In 2024, the oral segment is expected to dominate the India community acquired pneumonia drugs market

In 2024, the oral segment is expected to dominate the market with a market share of 57.48% due to advancements in oral formulation.

• On the basis of dosage, the market is segmented into tablet and solution. In 2024, the tablet segment is expected to dominate the market with a market share of 60.39%
•  On the basis of mode of purchase, the market is segmented into prescription and OTC. In 2024, the prescription segment is expected to dominate the market with a market share of 84.53%
• On the basis of product type, the market is segmented into generics and branded. In 2024, the generics segment is expected to dominate the market with a market share of 98.89%
• On the basis of type, the market is segmented into bacterial, virus, and fungi. In 2024, the bacterial segment is expected to dominate the market with a market share of 51.37%
• On the basis of population type, the market is segmented into children, geriatrics, and adults. In 2024, the children segment is expected to dominate the market with a market share of 49.68%
• On the basis of end user, the market is segmented into hospitals, specialty clinics, homecare, and others. In 2024, the hospitals segment is expected to dominate the market with a market share of 50.06%
• On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2024, the hospital pharmacy segment is expected to dominate the market with a market share of 53.09%

Major Players

Data Bridge Market Research analyzes Pfizer Inc., (U.S.) Cipla Inc. (India), AstraZeneca (U.K.), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel) as the major players of India community acquired pneumonia drugs market.

Market Developments

• In September 2023, Astrazeneca received an approval from the Central Drugs Standard Control Organisation (CDSCO) to import and market a medication to prevent the Respiratory Syncytial virus. This will help the company to strengthen its presence in the Indian market
• In May 2021, Teva Pharmaceutical Industries Ltd. announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the Reference Listed Drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals. This has helped the company to strengthen its product portfolio. In March 2021, according to an article published by Frontiers, India confronts a significant concern with multidrug-resistant pathogens causing pneumonia. A 2022 study in Delhi reported 72% of Carbapenem resistant Klebsiella pneumoniae isolates resistant to commonly used antibiotics, necessitating newer drug
• In December 2019, Fresenius Kabi announced the availability of Ertapenem for Injection in a 1-gram vial presentation. The new product is the generic equivalent of Invanz. Hence, the company has established its strong presence in the market with its product

For more detailed information about India community acquired pneumonia drugs market. Report, click here – https://www.databridgemarketresearch.com/reports/india-community-acquired-pneumonia-drugs-market